Vaccine Company, Inc. is a biotechnology firm focused on vaccine development using its proprietary In Vivo Nanoparticle (IVN) technology. This platform enables virus-like particle antigen presentation without conventional manufacturing processes. The company’s lead candidate is a five-antigen prophylactic vaccine against Epstein-Barr virus (EBV), currently Phase 1-ready, with potential applications in preventing infectious mononucleosis and reducing EBV-associated risks such as multiple sclerosis and certain malignancies.
None yet. When a new project in the record names Vaccine Company as owner, partner or investor, it shows here.
Adds a better-tolerated shingles vaccine, bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae and C. trachomatis, and nanoparticle EBV vaccine tech; deals include milestone payments.
